When the BoJ raised rates in March, it had been 17 years since it had last done so, though the world was very different then. While the July rate hike was unlikely to move the economic needle, the question now is what else might follow the subsequent financial market maelstrom. Pelham Smithers discusses the outlook for Japan’s macro environment, what new fiscal policies the new PM might introduce, how the BoJ might react and the all-important trend in corporate earnings. This then leads us to...
NITTO DENKO (JP), a company active in the Speciality Chemicals industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date March 25, 2022, the closing price was JPY 9,080.00 and its pote...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
OSAKA, Japon--(BUSINESS WIRE)-- En réponse à l’expansion rapide du marché des produits thérapeutiques à base d’oligonucléotides pouvant potentiellement traiter les maladies courantes comme les maladies réfractaires, (Siège : Osaka ; Président : Hideo Takasaki ; ci-après dénommée « Nitto ») va investir près de 25 milliards JPY dans (Siège : Massachusetts, États-Unis ; ci-après dénommée « Avecia »), une filiale de Nitto, et d’autres établissements commerciaux et sociétés associés du groupe. Cet investissement augmentera considérablement la capacité de production de son activité de produits thé...
OSAKA, Japan--(BUSINESS WIRE)-- In response to the rapid market expansion of oligonucleotide therapeutics that have potential to treat both common and intractable diseases, (Headquarters: Osaka; President: Hideo Takasaki; referred to hereafter as “Nitto”) will invest approximately 25 billion Japanese yen in (Headquarters: Massachusetts, USA; referred to hereafter as “Avecia”), a subsidiary of Nitto, and other related business establishments and group companies. This investment will significantly increase the manufacturing capacity of its oligonucleotide therapeutic business. This press rele...
Uncertainty Hits Global Equities MSCI ACWI (ACWI-US) recently broke below the $81.50 short-term support level we were watching, which tells us that the important $77 support level is likely to be tested. While a more cautious outlook is appropriate, as long as $77 holds (the September lows) we are constructive and would be buyers on a pullback. A move below $77 would start to get very concerning, and would leave $75 and the 200-day MA as last-ditch support. · Market Dynamics Still Cons...
Shares in Nitto Denko [ND] (6988 JP) eked out a 1% gain on May 1 which was the first day of trading after releasing earnings on Apr 27 – even though FY17 OP and FY18 OP guidance was below consensus estimates. The shares appear fully valued, but RoE remains relatively high, and some premium is warranted by ND’s drug development efforts
Apple iPhone Demand and OutlookTags: Apple (AAPL US), Hon Hai (2317 TT), Samsung Electronics (005930 KS), Japan Display (6740 JP), Nissha (7915 JP), Nitto Denko (6988 JP), Zeon Corp (4205 JP), Sumitomo Chemical (4005 JP)In the December quarter (2017) Apple (AAPL US) sold 77.3mil iPhones, which was down slightly on the 78.3mil sold a year earlier. This was below our expectation of 80mil units and we were probably mid-range (having been below consensus originally). However, ASPs came in higher tha...
The PSA Japan Research Round-Up for the week ending February 16, 2018 Contents at a Glanceï¶ The Weekly Comment by Pelham Smithers: Surf’s up: Pelham Smithers considers whether we are starting to see a break in the link between the yen and the Japanese stock market.ï¶ Reports / Flash Notes Summaries 1. Mitsubishi Electric (6503 JP): FA and Infrastructure Upturn 2. Sony (6758 JP): FY17 Outlook and SoTP5ï¶ Company / Sector / Thematic Comments 1. Sony (6758 JP) Surprises, Irritates with Peter Ra...
PSA Today Feb 15: Japan Market Comment by Pelham Smithers, Joel Scheiman and Thao Nguyen Nikkei ¥21,464.98 (+¥310.81/ +1.47%); Topix ¥1,719.27 (+¥16.55/ +0.97%); ¥/$106.56Tags: Remixpoint (3825 JP), SBI Holdings (8473 JP), mixi (2121 JP), Kirin (2503 JP), Sony (6758 JP), Facebook (FB US), Apple (AAPL US), Netflix (NFLX US), Capcom (9697 JP), Bandai Namco (7832 JP), Sumitomo Dainippon Pharma (4506 JP), Nitto Denko (6988 JP), Tokyo Ohka Kogyo (4186 JP), Nissha (7915 JP), Showa Denko (SDK, 4004 JP)...
PSA Today Jan 30: Japan Market Comment by Pelham Smithers, Joel Scheiman, Thao Nguyen and William Nestuk Nikkei ¥23,291.97 (-¥337.37 / -1.43%); Topix ¥1,858.13 (-¥22.32/ -1.19%); ¥/$108.61Tags: Apple (AAPL US), Nissha (7915 JP), TDK (6762 JP), Nitto Denko (6998 JP), Shin-Etsu Chemical (4063 JP), Sumitomo Chemical (4005 JP), Sumitomo Chemical (4005 JP), Murata (6981 JP), NOK (7240 JP), Dexerials (4980 JP), Hitachi Construction Machinery (6305 JP), Canon (7751 JP), Capcom (9697 JP), SBI Holdings (...
Nitto Denko (ND) announced results on April 28th, after which the shares responded positively to its stronger than expected Q4. FY17 OP guidance was close to consensus estimates, but achievement appears more certain after the stronger Q4. The volatile Optronics segment, particularly, finished FY16 on a strong note. A moderately weaker yen helped, as did stronger than expected demand for LCD polarizers in high-end Chinese smartphones. FY17 strategies are discussed and our revised estimates, plus...
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
MILFORD, Mass.--(BUSINESS WIRE)-- Nitto Denko Avecia Inc. (Avecia), today announced it has entered into a definitive agreement to acquire the assets of Irvine Pharmaceutical Services (Irvine) and Avrio Biopharmaceuticals (Avrio), both located in Irvine, CA. Irvine is a leading analytical development services provider and Avrio is a premier cGMP parenteral contract manufacturing organization. Avecia will consolidate both businesses into the newly established company, Nitto Avecia Pharma Services. The acquisitions of Irvine and...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.